Exploiting cis-acting replication elements to direct hepatitis C virus-dependent transgene expression

Area of Science:

• Virology
• Molecular Biology
• Gene Therapy

Background:

• Hepatitis C virus (HCV) infection poses a significant global health challenge.
• Current therapies have limitations, necessitating novel treatment strategies.
• Targeting viral replication machinery is a key approach for antiviral development.

Purpose of the Study:

• To develop a novel gene therapy strategy for targeting hepatitis C virus (HCV).
• To engineer a construct for HCV-specific gene expression.
• To demonstrate the efficacy of this strategy in antiviral therapy.

Main Methods:

• Engineered a construct with antisense sequence and EMCV IRES, flanked by HCV cDNA sequences.
• Utilized cis-acting replication elements for conditional transgene expression.
• Employed reporter assays and strand-specific RT-PCR for validation.
• Used cytosine deaminase suicide gene and adenovirus delivery for therapeutic demonstration.

Main Results:

• Selective transgene expression was observed in HCV replicon cells (Huh-7).
• Gene expression remained silent in uninfected cells.
• Cytosine deaminase was specifically expressed in replicon cells.
• Marked chemosensitization of replicon cells to flucytosine was achieved.

Conclusions:

• The novel gene therapy strategy effectively targets HCV replication.
• This approach enables selective gene expression in infected cells.
• The strategy holds potential for treating HCV and other single-stranded RNA viral infections.